Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task.

MD is a frequent complication in patients who are diagnosed with advanced cancer.

Topic Depression Palliative Care
Compound Placebo Ketamine
Country Mexico
Visit trial
Status Recruiting
Results Published No
Start date 19 November 2019
End date 19 December 2022
Chance of happening 100%
Phase Phase I Phase II
Design Blinded
Type Interventional
Generation First
Participants 24
Sex All
Age 18- 65
Therapy No

Trial Details

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1). MD is a frequent complication in patients who are diagnosed with advanced cancer.

NCT Number NCT04471818

Sponsors & Collaborators

Instituto Nacional de Cancerologia de Mexico
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.